GM3

GM3 (monosialodihexosylganglioside) is a type of ganglioside. The letter G refers to ganglioside, and M is for monosialic acid as it has only one sialic acid group. The numbering is based on its relative mobility in electrophoresis among other monosialic gangliosides.[1] Its structure can be condensed to NANA-Gal-Glc-ceramide. GM3 is the most common membrane-bound glycosphingolipid in tissues, composed of three monosaccharide groups attached to a ceramide backbone.[2] GM3 serves as a precursor for other, more complex gangliosides. Like other gangliosides, GM3 is synthesized in the Golgi apparatus. It is then transported to the plasma membrane, where it functions in cellular signaling.[2] GM3 also functions as an inhibitor; it inhibits cell growth, the function of growth factor receptors, and generation of cytokines by T cells.[3]

Applications in cancer treatment

The immunologic function of GM3 in inhibiting proliferation has resulted in its usage in the study of cancer biology and cancer treatments. GM3 has been found to reduce the motility of ovarian cancer cells, colorectal cancer cells, and gastric cancer cells. High amounts of GM3 also displayed a high amount of caveolin-1, a molecule which has been shown to inhibit ovarian cancer growth.[4] In bladder cancer cells, GM3 show antiproliferative effects. Increased concentrations of GM3 in bladder cancer cells reduces the malignancy potential of those cells and induces apoptosis.[5] The addition of GM3 to bladder cancer cells also decreases their cell adhesion and inhibits tumor growth.[6] Due to its role in inhibiting cancer growth, GM3 is a target of cancer treatments. The chemotherapy drug cisplatin functions by inducing GM3-mediated apoptosis of cancer cells.[5]

References
  1. Puri D (2011). Biochemistry. ISBN 978-81-312-2312-3.
  2. Chan RB, Perotte AJ, Zhou B, Liong C, Shorr EJ, Marder KS, et al. (2017-02-17). "Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysis". PLOS ONE. 12 (2): e0172348. Bibcode:2017PLoSO..1272348C. doi:10.1371/journal.pone.0172348. PMC 5315374. PMID 28212433.
  3. Tsukuda Y, Iwasaki N, Seito N, Kanayama M, Fujitani N, Shinohara Y, Kasahara Y, Onodera T, Suzuki K, Asano T, Minami A, Yamashita T (2012-06-29). Rojas M (ed.). "Ganglioside GM3 has an essential role in the pathogenesis and progression of rheumatoid arthritis". PLOS ONE. 7 (6): e40136. Bibcode:2012PLoSO...740136T. doi:10.1371/journal.pone.0040136. PMC 3387008. PMID 22768242.
  4. Hakomori SI (May 2010). "Glycosynaptic microdomains controlling tumor cell phenotype through alteration of cell growth, adhesion, and motility". FEBS Letters. 584 (9): 1901–6. doi:10.1016/j.febslet.2009.10.065. PMC 2867360. PMID 19874824.
  5. Chung TW, Choi HJ, Kim SJ, Kwak CH, Song KH, Jin UH, Chang YC, Chang HW, Lee YC, Ha KT, Kim CH (2014-05-14). "The ganglioside GM3 is associated with cisplatin-induced apoptosis in human colon cancer cells". PLOS ONE. 9 (5): e92786. Bibcode:2014PLoSO...992786C. doi:10.1371/journal.pone.0092786. PMC 4020741. PMID 24829158.
  6. Wang H, Isaji T, Satoh M, Li D, Arai Y, Gu J (January 2013). "Antitumor effects of exogenous ganglioside GM3 on bladder cancer in an orthotopic cancer model". Urology. 81 (1): 210.e11–5. doi:10.1016/j.urology.2012.08.015. PMID 23102779.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.